Real-world cardiovascular disease burden in patients with atherosclerotic cardiovascular disease: a comprehensive systematic literature review

References

• Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation 2010;121:948-54
   PubMed Web of Science ®Google Scholar
• Nichols M, Townsend N, Scarborough P, et al. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J 2014;35:2950-9
   PubMed Web of Science ®Google Scholar
• Global status report on noncommunicable diseases 2014. Geneva, Switzerland: WHO Press, 2014. Available at: http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf?ua =1 [Last accessed 7 August 2017]
   Google Scholar
• Cardiovascular disease: a costly burden for America projections through 2035. 2017. Available at: http://www.heart.org/idc/groups/heart-public/@wcm/@adv/documents/downloadable/ucm_491543.pdf [Last accessed 7 August 2017]
   Google Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016;253:281-344
   PubMed Web of Science ®Google Scholar
• FastStats: Heart Disease. CDC/National Center for Health Statistics; 2017. Available at: https://www.cdc.gov/nchs/fastats/heart-disease.htm [Last accessed 7 August 2017]
   Google Scholar
• Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. 2012. Available at: https://www.nhlbi.nih.gov/files/docs/research/2012_ChartBook.pdf [Last accessed 4 April 2017]
   Google Scholar
• Fleg JL, Forman DE, Berra K, et al. Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association. Circulation 2013;128:2422-46
   PubMed Web of Science ®Google Scholar
• Roy S. Atherosclerotic cardiovascular disease risk and evidence-based management of cholesterol. North Am J Med Sci 2014;6:191-8
   PubMedGoogle Scholar
• Lambert M. ACC/AHA release updated guideline on the treatment of blood cholesterol to reduce ASCVD risk. Am Fam Physician 2014;90:260-5
   Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics – 2015 update: a report from the American Heart Association. Circulation 2015;131:e29-322
   PubMed Web of Science ®Google Scholar
• Elliott L, Fidler C, Ditchfield A, et al. Hypoglycemia event rates: a comparison between real-world data and randomized controlled trial populations in insulin-treated diabetes. Diabetes Ther 2016;7:45-60
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9, W64
   PubMed Web of Science ®Google Scholar
• Robinson KA, Saldanha IJ, Mckoy NA. Development of a framework to identify research gaps from systematic reviews. J Clin Epidemiol 2011;64:1325-30
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet Lond Engl 2010;376:1670-81
   PubMed Web of Science ®Google Scholar
• Hartling L, Hamm M, Milne A, et al. Validity and Inter-Rater Reliability Testing of Quality Assessment Instruments. Rockville (MD): Agency for Healthcare Research and Quality (US), 2012. Available at: http://www.ncbi.nlm.nih.gov/books/NBK92293/ [Last accessed 5 April 2017]
   Google Scholar
• The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp [Last accessed 30 March 2017]
   Google Scholar
• Chen P-S, Cheng C-L, Kao Yang Y-H, et al. Impact of early statin therapy in patients with ischemic stroke or transient ischemic attack. Acta Neurol Scand 2014;129:41-8
   PubMed Web of Science ®Google Scholar
• Chen P-S, Cheng C-L, Kao Yang Y-H, et al. Statin adherence after ischemic stroke or transient ischemic attack is associated with clinical outcome. Circ J 2016;80:731-7
   PubMed Web of Science ®Google Scholar
• Chinwong D, Patumanond J, Chinwong S, et al. Low-density lipoprotein cholesterol of less than 70 mg/dL is associated with fewer cardiovascular events in acute coronary syndrome patients: a real-life cohort in Thailand. Ther Clin Risk Manag 2015;11:659-67
   PubMed Web of Science ®Google Scholar
• Danese MD, Gleeson M, Kutikova L, et al. Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK. BMJ Open 2016;6:e011805. doi: 10.1136/bmjopen-2016-011805
   PubMed Web of Science ®Google Scholar
• Huang Q, Grabner M, Sanchez RJ, et al. Clinical characteristics and unmet need among patients with atherosclerotic cardiovascular disease stratified by statin use. Am Health Drug Benefits 2016;9:434-44
   PubMed Web of Science ®Google Scholar
• Jena AB, Blumenthal DM, Stevens W, et al. Value of improved lipid control in patients at high risk for adverse cardiac events. Am J Manag Care 2016;22:e199-207
   PubMed Web of Science ®Google Scholar
• Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic heart disease taking statin treatment. JAMA Intern Med 2016;176:1105-13
   PubMed Web of Science ®Google Scholar
• Lin Wu F-L, Wang J, Ho W, et al. Effectiveness of a combination of ezetimibe and statins in patients with acute coronary syndrome and multiple comorbidities: a 6-year population-based cohort study. Int J Cardiol 2017;233:43-51
   PubMed Web of Science ®Google Scholar
• Ostergaard K, Pottegård A, Hallas J, et al. Discontinuation of antiplatelet treatment and risk of recurrent stroke and all-cause death: a cohort study. Neuroepidemiology 2014;43:57-64
   PubMed Web of Science ®Google Scholar
• Sheng X, Murphy MJ, MacDonald TM, et al. Effect of statins on total cholesterol concentrations and cardiovascular outcomes in patients with diabetes mellitus: a population-based cohort study. Eur J Clin Pharmacol 2012;68:1201-8
   PubMed Web of Science ®Google Scholar
• Sheng X, Murphy MJ, MacDonald TM, et al. Effectiveness of statins in chronic kidney disease. QJM 2012;105:641-8
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Planas-Comes A, Frias-Garrido X, et al. Statins after recent stroke reduces recurrence and improves survival in an aging Mediterranean population without known coronary heart disease: stroke secondary prevention with statins. J Clin Pharm Ther 2012;37:441-7
   PubMed Web of Science ®Google Scholar
• Smith DH, Johnson ES, Boudreau DM, et al. Comparative effectiveness of statin therapy in chronic kidney disease and acute myocardial infarction: a retrospective cohort study. Am J Med 2015;128:1252.e1-11
   PubMed Web of Science ®Google Scholar
• Toth PP, Danese M, Villa G, et al. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. J Med Econ 2017;20:555-64
   PubMed Web of Science ®Google Scholar
• Mahajan R. Real world data: additional source for making clinical decisions. Int J Appl Basic Med Res 2015;5:82
   PubMedGoogle Scholar
• Sullivan GM. Getting off the “gold standard”: randomized controlled trials and education research. J Grad Med Educ 2011;3:285-9
   PubMedGoogle Scholar
• Toth PP, Stevens W, Chou JW. Why published studies of the cost-effectiveness of PCSK-9 inhibitors yielded such markedly different results. J Med Econ 2017;20:749-51
   PubMed Web of Science ®Google Scholar
• Atar D, Ong S, Lansberg PJ. Expanding the evidence base: comparing randomized controlled trials and observational studies of statins. Am J Ther 2015;22:e141-50
   PubMed Web of Science ®Google Scholar
• Deaton C, Froelicher ES, Wu LH, et al. The global burden of cardiovascular disease. Eur J Cardiovasc Nurs 2011;10(Suppl2):S5-S13
   Web of Science ®Google Scholar
• Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011;123:933-44
   PubMed Web of Science ®Google Scholar
• Majeed A, Aylin P. The ageing population of the United Kingdom and cardiovascular disease. BMJ 2005;331:1362
   PubMed Web of Science ®Google Scholar
• Moran A, Gu D, Zhao D, et al. Future cardiovascular disease in China: Markov model and risk factor scenario projections from the Coronary Heart Disease Policy Model–China. Circ Cardiovasc Qual Outcomes 2010;3:243-52
   PubMed Web of Science ®Google Scholar
• Odden MC, Coxson PG, Moran A, et al. The impact of the aging population on coronary heart disease in the United States. Am J Med 2011;124:827-33.e5
   PubMed Web of Science ®Google Scholar
• Vigen R, Maddox TM, Allen LA. Aging of the United States population: impact on heart failure. Curr Heart Fail Rep 2012;9:369-74
   PubMedGoogle Scholar
• Roth GA, Huffman MD, Moran AE, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation 2015;132:1667-78
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Backer G, et al.; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373:929-40
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Bacquer D, et al.; EUROASPIRE Investigators. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016;23:636-48
   PubMed Web of Science ®Google Scholar
• Sasieni PD, Wald NJ. Should a reduction in all-cause mortality be the goal when assessing preventive medical therapies? Circulation 2017;135:1985-7
   PubMed Web of Science ®Google Scholar